Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 6/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352932 | 0.90 | MAPK1 (0.34) | KDM4ELMNAFAAHESR1CHRM1 | |
| SCHEMBL5353271 | 0.89 | LMNA (0.34) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL5343892 | 0.87 | LMNA (0.45) | KDM4ELMNAFAAHRORCESR1 | |
| SCHEMBL14517753 | 0.86 | FAAH (0.33) | FAAHMGLL | |
| SCHEMBL5353135 | 0.85 | RAB9A (0.41) | KDM4ELMNAFAAHRORC | |
| SCHEMBL5344996 | 0.84 | SYK (0.39) | LMNA | |
| SCHEMBL5340966 | 0.84 | CYP2D6 (0.35) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL5343565 | 0.83 | GRM2 (0.38) | KDM4ELMNAFAAHESR1CHRM1 | |
| SCHEMBL5344796 | 0.82 | BCL2 (0.34) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL5340133 | 0.81 | ADAMTS4 (0.35) | KDM4ELMNAESR1CHRM1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20050020566-A1 | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1443047-A1 | NOVEL CARBAPENEM COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020566-A1 | Novel carbapenem compounds | HPN, PRSS1, BPGM | KDM4E 3734/4885LMNA 366/4885FAAH 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.